Detailed Information on Publication Record
2015
Patient with inoperable pheochromocytoma
BRANČÍKOVÁ, Dagmar, Zdeněk MECHL, Zdeněk ADAM, Eva JANDÁKOVÁ, Zdeněk PAVLOVSKÝ et. al.Basic information
Original name
Patient with inoperable pheochromocytoma
Authors
BRANČÍKOVÁ, Dagmar (203 Czech Republic, guarantor, belonging to the institution), Zdeněk MECHL (203 Czech Republic), Zdeněk ADAM (203 Czech Republic, belonging to the institution), Eva JANDÁKOVÁ (203 Czech Republic, belonging to the institution), Zdeněk PAVLOVSKÝ (203 Czech Republic, belonging to the institution), Vlastimil VÁLEK (203 Czech Republic, belonging to the institution) and Tomáš ANDRAŠINA (703 Slovakia, belonging to the institution)
Edition
Current Oncology, Toronto, Multimed INC. 2015, 1198-0052
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30200 3.2 Clinical medicine
Country of publisher
Canada
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 1.829
RIV identification code
RIV/00216224:14110/15:00083405
Organization unit
Faculty of Medicine
UT WoS
000356976100010
Keywords in English
Pheochromocytoma; chemoembolization; lanreotide
Tags
Tags
International impact, Reviewed
Změněno: 13/1/2016 14:16, Ing. Mgr. Věra Pospíšilíková
Abstract
V originále
Malignant pheochromocytoma is a tumour with a very low incidence that occurs sporadically or in the presence of multiple endocrine neoplasia. We present the case of a woman with a sporadic occurrence of pheochromocytoma diagnosed in the phase of multiple dissemination in the abdominal cavity and overexpressing adrenaline, noradrenaline, and dopamine. Local transarterial chemoembolization and systemic treatment with lanreotide resulted in a very good response, a decrease in the production of catecholamines for 12 months and a partial decrease for another 8 months, with stabilization of disease determined by imaging. Systemic treatment with tegafur resulted in disease stabilization lasting 50 months, after which the drug was discontinued because of adverse effects. Maintenance therapy with lanreotide continues, and no disease progression has been observed for 4 months. The treatment algorithm for such patients is multidisciplinary and must always take into account the current scope of the disease, intercurrence, and the general condition of the patient.